Abstract
Diabetic nephropathy (DN), a severe diabetes complication, causes kidney morphological and structural changes due to extracellular matrix accumulation. This accumulation is caused mainly by oxidative stress. Semi-essential amino acid derivative taurine has powerful antioxidant and antifibrotic effects. The aim of this study was to investigate the renoprotective effects of taurine through its possible roles in oxidative stress, extracellular matrix proteins, and the signaling pathways associated with the accumulation of extracellular matrix proteins in DN rats. 29 Wistar albino rats were randomly separated into control, taurine, diabetes, and diabetes + taurine groups. Diabetes animals were injected 45 mg/kg streptozosine. Taurine is given by adding to drinking water as 1% (w/v). Urine, serum, and kidney tissue were collected from rats for biochemical and histological analysis after 12 weeks. According to the studies, taurine significantly reduces the levels of malondialdehyde (MDA), total oxidant status (TOS), and protein expression of NADPH oxidase 4 (NOX4) that increase in diabetic kidney tissue. Also, decreased superoxide dismutase (SOD) activity levels significantly increased with taurine in diabetic rats. Moreover, increased mRNA and protein levels of fibronectin decreased with taurine. The matrix metalloproteinase (MMP)-2 and MMP-9 activities and their mRNA levels increased significantly, and this increase was significantly summed with taurine. There was a decrease in mRNA expression of Extracellular matrix metalloproteinase inducer (EMMPRIN). Taurine significantly increased this decrease. Diabetes increased mRNA expressions of transforming growth factor (TGF)-β and Smad2/3. Taurine significantly reduced this induction. TGF-β protein expression, p38, and Smad2/3 activations were also inhibited, but taurine was suppressed significantly. All these findings indicate that taurine may be an effective practical strategy to prevent renal diabetic injury.
Similar content being viewed by others
Data availability
The data underlying this article are available in the article.
References
Agrawal SM, Yong VW (2011) The many faces of EMMPRIN-roles in neuroinflammation. Biochimica Et Biophysica Acta - Mol Basis Dis 1812(2):213–219. https://doi.org/10.1016/j.bbadis.2010.07.018
Baliou S, Adamaki M, Ioannou P, Pappa A, Panayiotidis M, Christodoulou I, Spandidos D, Kyriakopoulos A, Zoumpourlis V (2021) Ameliorative effect of taurine against diabetes and renal-associated disorders (Review). Med Int. https://doi.org/10.3892/mi.2021.3
Catania JM, Chen G, Parrish AR (2007) Role of matrix metalloproteinases in renal pathophysiologies. Am J Physiol Renal Physiol 292:905–911. https://doi.org/10.1152/ajprenal.00421.2006.-Matrix
Chesney RW, HanX, Patters AB (2010) Taurine and the renal system. J Biomed Sci 17 Suppl 1(Suppl 1):S4
Chomczynski P (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15(3):532-4, 536-7
Conway BR, Betz B, Sheldrake TA, Manning JR, Dunbar DR, Dobyns A, Hughes J, Mullins JJ (2014) Tight blood glycaemic and blood pressure control in experimental diabetic nephropathy reduces extracellular matrix production without regression of fibrosis. Nephrology 19(12):802–813. https://doi.org/10.1111/nep.12335
Das J, Sil PC (2012) Taurine ameliorates alloxan-induced diabetic renal injury, oxidative stress-related signaling pathways and apoptosis in rats. Amino Acids 43(4):1509–1523. https://doi.org/10.1007/s00726-012-1225-y
Das J, Ghosh J, Manna P, Sil PC (2010) Taurine protects acetaminophen-induced oxidative damage in mice kidney through APAP urinary excretion and CYP2E1 inactivation. Toxicology 269(1):24–34. https://doi.org/10.1016/j.tox.2010.01.003
De Almeida LGN, Thode H, Eslambolchi Y, Chopra S, Young D, Gill S, Devel L, Dufour A (2022) Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology. Pharmacol Rev 74(3):712–768
Ferreira IMPLVO, Nunes MV, Mendes E, Remião F, Ferreira MA (1997) Development of an HPLC-UV method for determination of taurine in infant formulae and breast milk. J Liq Chromatogr Relat Technol 20(8):1269–1278. https://doi.org/10.1080/10826079708010975
Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM, Vergara A, Orbe J, Soler MJ (2020) Matrix metalloproteinases in diabetic kidney disease. J Clin Med. https://doi.org/10.3390/jcm9020472
Guneli E, Tugyan K, Ozturk H, Gumustekin M, Cilaker S, Uysal N (2008) Effect of melatonin on testicular damage in streptozotocin-induced diabetes rats. Eur Surg Res 40(4):354–360. https://doi.org/10.1159/000118032
Ha H, Yu M-R, Kim KH (1999) Melatonin and taurine reduce early glomerulopathy in diabetic rats. Free Radic Biol Med 26(7–8):944–950
Han X, Chesney RW (2012) The role of taurine in renal disorders. Amino Acids. https://doi.org/10.1007/s00726-012-1314-y
Han J, Pang X, Zhang Y, Peng Z, Shi X, Xing Y (2020) Hirudin protects against kidney damage in streptozotocin-induced diabetic nephropathy rats by inhibiting inflammation via P38 MAPK/NF-κB pathway. Drug Des Dev Ther 14:3223–3234
He T, Guan X, Wang S, Xiao T, Yang K, Xu X, Wang J, Zhao J (2015) Resveratrol prevents high glucose-induced epithelial-mesenchymal transition in renal tubular epithelial cells by inhibiting NADPH oxidase/ROS/ERK pathway. Mol Cell Endocrinol 402:13–20. https://doi.org/10.1016/j.mce.2014.12.010
Higo S, Miyata S, Yun Jiang Q, Kitazawa R, Kitazawa S, Kasuga M (2018) Taurine administration after appearance of proteinuria retards progression of diabetic nephropathy in rats. Kobe J Med Sci 54(1):E35–E45
Huang J-S, Chuang L-Y, Guh J-Y, Huang Y-J, Hsu M-S, Huang J-S, Chuang L-Y, Guh J-Y, Huang Y-J (2007) Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Phys-Iol 293:1072–1082. https://doi.org/10.1152/ajprenal.00020.2007.-Hyperglycemia-induced
Huang JS, Chuang LY, Guh JY, Yang YL, Hsu MS (2008a) Effect of taurine on advanced glycation end products-induced hypertrophy in renal tubular epithelial cells. Toxicol Appl Pharmacol 233(2):220–226. https://doi.org/10.1016/j.taap.2008.09.002
Huang Z, Wang C, Wei L, Wang J, Fan Y, Wang L, Wang Y, Chen T (2008b) Resveratrol inhibits EMMPRIN expression via P38 and ERK1/2 pathways in PMA-induced THP-1 cells. Biochem Biophys Res Commun 374(3):517–521. https://doi.org/10.1016/j.bbrc.2008.07.058
Huang JS, Chuang LY, Guh JY, Huang YJ (2009) Effects of nitric oxide and antioxidants on advanced glycation end products-induced hypertrophic growth in human renal tubular cells. Toxicol Sci 111(1):109–119. https://doi.org/10.1093/toxsci/kfp134
Huang WJ, Liu WJ, Xiao YH, Zheng HJ, Xiao Y, Jia Q, Jiang HX, Zhu ZB, Xia CH, Han XT, Sun RX, Nan H, Feng ZD, Wang SD, Zhao JX (2020) Tripterygium and its extracts for diabetic nephropathy: Efficacy and pharmacological mechanisms. Biomed Pharmacother. https://doi.org/10.1016/j.biopha.2019.109599
Ji L, Yin X-X, Wu Z-M, Wang J-Y, Lu Q, Gao Y-Y (2009) Ginkgo Biloba prevents glucose-induced accumulation of ECM 477 Ginkgo Biloba extract prevents glucose-induced accumulation of ECM in rat mesangial cells. Phytother Res 23:477–485. https://doi.org/10.1002/ptr
Jiang F, Liu GS, Dusting GJ, Chan EC (2014) NADPH oxidase-dependent redox signaling in TGF-β-mediated fibrotic responses. Redox Biol 20(2):267–272. https://doi.org/10.1016/j.redox.2014.01.012
Kandhare AD, Mukherjee A, Bodhankar SL (2017) Antioxidant for treatment of diabetic nephropathy: a systematic review and meta-analysis. Chemico-Biol Interact 278:212–221. https://doi.org/10.1016/j.cbi.2017.10.031
Kato T, Tsunekawa M, Wang S, Yamashita T, Ma N (2017) Effect of taurine on iNOS-mediated DNA damage in drug-induced renal injury. Adv Exp Med Biol 975:717–727. https://doi.org/10.1007/978-94-024-1079-2_56
Koh JH, Lee ES, Hyun M, Kim HM, Choi YJ, Lee EY, Yadav D, Chung CH (2014) Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model. Int J Endocrinol. https://doi.org/10.1155/2014/397307
Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680–685. https://doi.org/10.1038/227680a0
Lan HY (2012) Transforming growth factor-β/Smad signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol 39(8):731–738. https://doi.org/10.1111/j.1440-1681.2011.05663.x
Lee MPS, Sweeney G (2006) Insulin increases gelatinase activity in rat glomerular mesangial cells via ERK- and PI-3 kinase-dependent signalling. Diabetes Obes Metab 8(3):281–288. https://doi.org/10.1111/j.1463-1326.2005.00502.x
Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, Lee HB (2005) Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int 67:1762–1771
Lee SR, An EJ, Kim J, Bae YS (2020) Function of NADPH oxidases in diabetic nephropathy and development of nox inhibitors. Biomol Ther Korean Soc Appl Pharmacol 28(1):25–33. https://doi.org/10.4062/biomolther.2019.188
Lin S, Yang J, Wu G, Liu M, Luan X, Lv Q, Zhao H, Hu J (2010) Preventive effect of taurine on experimental type II diabetic nephropathy. J Biomed Sci 17 Suppl 1(Suppl 1):S46
Lykkesfeldt J (2001) Determination of malondialdehyde as dithiobarbituric acid adduct in biological samples by HPLC with fluorescence detection: comparison with ultraviolet-visible spectrophotometry. Clin Chem 47(9):1725–1727
Newsholme P, Cruzat VF, Keane KN, Carlessi R, de Bittencourt PI Jr (2016) Molecular mechanisms of ROS production and oxidative stress in diabetes. Biochem J 473(24):4527–4550. https://doi.org/10.1042/BCJ20160503C
Okazaki Y, Yamasaki Y, Uchida HA, Okamoto K, Satoh M, Maruyama K, Maeshima Y, Sugiyama H, Sugaya T, Kashihara N, Makino H (2007) Enhanced TGF-β/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor. Clin Exp Nephrol 11(1):77–87. https://doi.org/10.1007/s10157-006-0456-1
Pandya KG, Budhram R, Clark G, Lau-Cam CA (2013) Comparative evaluation of taurine and thiotaurine as protectants against diabetes-induced nephropathy in a rat model. Adv Exp Med Biol 775:371–394. https://doi.org/10.1007/978-1-4614-6130-2_29
Pandya K, Clark GJ, Lau-Cam CA (2017) Investigation of the role of a supplementation with taurine on the effects of hypoglycemic-hypotensive therapy against diabetes-induced nephrotoxicity in rats. Adv Exp Med Biol 975:371–400. https://doi.org/10.1007/978-94-024-1079-2_32
Park SH, Choi HJ, Lee JH, Woo CH, Kim JH, Han HJ (2001) High glucose inhibits renal proximal tubule cell proliferation and involves PKC, oxidative stress, and TGF-1. Kidney Int 59(5):1695–1705
Qing-Hua G, Ju-Ming L, Chang-Yu P, Zhao-Hui L, Xiao-Man Z, Yi-Ming M (2008) The kidney expression of matrix metalloproteinase-9 in the diabetic nephropathy of Kkay mice. J Diabetes Complic 22(6):408–412. https://doi.org/10.1016/j.jdiacomp.2007.10.002
Ripps H, Shen W (2012) Review: taurine: a “very essential” amino acid. Mol Vis 18:2673–2686
Roy A, Manna P, Sil PC (2009) Prophylactic role of taurine on arsenic mediated oxidative renal dysfunction via MAPKs/NF-B and mitochondria dependent pathways. Free Radical Res 43(10):995–1007. https://doi.org/10.1080/10715760903164998
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3(6):1101–1108. https://doi.org/10.1038/nprot.2008.73
Sedeek M, Nasrallah R, Touyz RM, Hébert RL (2013) NADPH oxidases, reactive oxygen species, and the kidney: Friend and foe. J Am Soc Nephrol 24(10):1512–1518. https://doi.org/10.1681/ASN.2012111112
Tang SCW, Lai KN (2012) The pathogenic role of the renal proximal tubular cell in diabetic nephropathy. Nephrol Dial Transplant 27(8):3049–3056. https://doi.org/10.1093/ndt/gfs260
Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK (2016) Extracellular matrix structure. Advanced drug delivery reviews, vol 97. Elsevier BV, Amsterdam, pp 4–27. https://doi.org/10.1016/j.addr.2015.11.001
Trachtman H, Futterweit S, Maesaka J, Ma C, Valderrama E, Fuchs A, Tarectecan AA, Rao PS, Sturman JA, Boles TH, Fu M-X, Baynes J, Mae-Saka J, Stur-Man JA (1995) Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats. Am J Physiol 269(3 Pt 2):F429–F438
Wang JN, Yang Q, Yang C, Cai YT, Xing T, Gao L, Wang F, Chen X, Liu XQ, He XY, Wei B, Jiang L, Li C, Jin J, Wen JG, Ma TT, Chen HY, Li J, Meng XM (2020) Smad3 promotes AKI sensitivity in diabetic mice via interaction with p53 and induction of NOX4-dependent ROS production. Redox Biol. https://doi.org/10.1016/j.redox.2020.101479
Wang L, Wang HL, Liu TT, Lan HY (2021) TGF-beta as a master regulator of diabetic nephropathy. Int J Mol Sci. https://doi.org/10.3390/ijms22157881
Wiechelman KJ., Braun RD, Fitzpatrick JD, Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1988) Investigation of the bicinchoninic acid protein assay: identification of the groups responsible for color formation. Anal Biochem 175(1):231–237
Winiarska K, Szymanski K, Gorniak P, Dudziak M, Bryla J (2009) Hypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits. Biochimie 91(2):261–270. https://doi.org/10.1016/j.biochi.2008.09.006
Yaribeygi H, Sathyapalan T, Atkin SL, Sahebkar A (2020) Molecular mechanisms linking oxidative stress and diabetes mellitus. Oxid Med Cell Longev 2020:8609213. https://doi.org/10.1155/2020/8609213
Yasuda H, Yuen PST, Hu X, Zhou H, Star RA (2006) Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 69(9):1535–1542. https://doi.org/10.1038/sj.ki.5000300
Zeng LF, Xiao Y, Sun L (2019) A glimpse of the mechanisms related to renal fibrosis in diabetic nephropathy. Adv Exp Med Biol 1165:49–79. https://doi.org/10.1007/978-981-13-8871-2_4
Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma J-X (2006) Therapeutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol 17:475–486. https://doi.org/10.1681/ASN.2005020217
Zhou L, Fu P, Ru Huang X, Liu F, Chung ACK, Neng Lai K, Yao Lan H (2010) Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol 298:1006–1017. https://doi.org/10.1152/ajprenal.00675.2009.-Aristolochic
Acknowledgements
This research was funded by Dokuz Eylul University Research Project Administration (Project number: 2017.KB.SAG.024) and carried out at Dokuz Eylul University Medical School Learning Resources Center Research Laboratory (R-LAB).
Author information
Authors and Affiliations
Contributions
The article's first author, CU, was responsible for carrying out the experiments and authoring the article. AC performed the animal model experiment and provided its follow-up. SO conducted histological evaluations. EG, SA, BE, CC, and GA supported the first author in analyzing and discussing the data relevant to their specific field. ZC is CU doctoral advisor and the director of this project. All authors reviewed the manuscript
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Handling editor: S. Broer.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Ural, C., Celik, A., Ozbal, S. et al. The renoprotective effects of taurine against diabetic nephropathy via the p38 MAPK and TGF-β/Smad2/3 signaling pathways. Amino Acids 55, 1665–1677 (2023). https://doi.org/10.1007/s00726-023-03342-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-023-03342-w